Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Insulin for Hyperglycemia in Hospitalized Oncology Patients
NCT03904199Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Apr 2019
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in hyperglycemia comparing Basal-Prandial-Correctional Insulin with Standard of Care Insulin (2 arms). Primary endpoint: Proportion of blood glucose values within normal range up to 30 days. Started Apr 2019; status: completed.
02
Drugs
human insulin
03
Conditions
hyperglycemia
Beyond the preview
Go deeper on NCT03904199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904199.